Stem Cells Market

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global immunohematology market was valued at US$ 10.57 billion in 2020 and is expected to register a revenue CAGR of 7.9% to reach US$ 24.4 billion by 2031.

Market Fundamentals

Stem cells are cells that have the unique ability to develop into different cell types called daughter cells. These new cells can range from muscle cells to brain cells. They help in replacing the damaged cells in the body. There are different types of stem cells including embryonic stem cells, adult stem cells, induced pluripotent stem cells, and perinatal stem cells. Different types of cells have different origins. Embryonic stem cells are derived from embryos that are three to five days old, and adult stem cells are derived from adult tissues such as bone marrow. Perinatal stem cells are derived from the amniotic fluid as well as umbilical cord blood. As stem cells have the potential to repair damaged tissue, scientists are conducting several studies on stem cells to cure various diseases or disorders.

[674523]

Market Dynamics

Growing public-private funding for stem cell research and the rising awareness related to therapeutic applications of stem cells are some of the factors driving the revenue growth of the stem cell market. Moreover, factors such as the increasing prevalence of chronic diseases such as cancer, the rising number of R&D activities related to stem cells, and the increasing demand for regenerative medicine are expected to boost the stem cell market revenue growth during the forecast period. However, ethical concerns and the possible risk of oncogene expression during the reprogramming of the cells are some of the factors likely to hinder the market revenue growth to some extent.

Market Ecosystem

The global stem cell market is analyzed from four perspectives: cell source, type, application, and region.

Stem Cells Market by Cell Source

Based on cell source, the stem cells market is segmented into human embryonic stem cells, adult stem cells, induced pluripotent stem cells, and other types of stem cells. 

Adult stem cells are the most used cell type and account for the largest share of the stem cell market. Major factors attributing to the growth of this segment include low chances of rejection by the body and a high success rate. Moreover, as adult stem cells can be transformed into pluripotent stem cells, they have advantages over embryonic cells without affecting the embryo. These factors are positively driving the use of these types of cells.

Stem Cells Market by Type

Based on type, the stem cells market is segmented into allogeneic stem cell therapy and autologous stem cell therapy. 

Autologous stem cell therapy is expected to be the fastest-growing segment during the forecast period. Advantages such as reduced chances of infection from an unknown donor and lower chances of rejection by the body are driving the segmental revenue growth.

Stem Cells Market by Application

[654235]

Based on application, the stem cells market is segmented into regenerative medicine and drug discovery & development. 

Regenerative medicine segment accounts for the largest revenue share of the stem cell market. Factors attributing to the revenue growth of this segment include the rising number of research activities in the field of regenerative medicine using stem cells and the increasing prevalence of cancer. Moreover, growing awareness related to regenerative medicine for the replacement of damaged tissues is also driving their use.

Stem Cells Market by Region

Based on region, the global stem cells market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). 

North America accounts for the largest revenue share of the global stem cells market. Major factors attributing to the revenue growth of the stem cells market in this region include the rising public-private funding for R&D activities of regenerative medicine, increasing prevalence of chronic infectious diseases, and the presence of prominent players. Moreover, several ongoing studies using stem cells in the field of oncology, musculoskeletal disorders, and CNS disorders are further expected to fuel the market revenue growth rate during the forecast period.

Competitive Landscape

The prominent players operating in the global stem cells market include:

• Pfizer Inc.
• Osiris Therapeutics, Inc. (Smith & Nephew)
• ReNeuron Group plc
• GlaxoSmithKline plc
• Holostem Terapie Avanzate S.r.l.
• Baxter
• AlloSource
• Astellas Pharma Inc.
• Pluristem Therapeutics Inc.
• Regen BioPharma, Inc.

Strategic Developments

• In February 2021, Evotec SE entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf for the development of a cell therapy for the treatment of heart failure.
• In August 2020, Pluristem Therapeutics Inc. signed a non-binding Memorandum of Understanding (MOU) with the United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC), a healthcare center focused on cell therapy and regenerative medicine.
• In May 2020, CiRA Foundation and the Cell and Gene Therapy Catapult launched a new collaborative research project focused on the induced pluripotent stem (iPS) cell characterization. This project mainly focused on finding applications of iPS cell technologies for the manufacture of regenerative medicine products.
• In April 2020, HebeCell Corp (U.S.) raised US$ 10 million in Pre-Series A financing from Aceso Biotech Venture Fund for advancing their development of natural killer cells (NK cells) engineered human pluripotent stem cells (hPSC) in the U.S. and outside the U.S.
• In April 2020, scientists of the Diabetes Research Institute and Cell Transplant Center at the University of Miami Miller School of Medicine were granted immediate FDA authorization for a 24 patients clinical trial to test the safety and efficacy of umbilical cord-derived mesenchymal stem cells to block the life-threatening lung inflammation that accompanies severe cases of COVID-19.
• In April 2020, Fate Therapeutics entered into a multi-year collaboration with Janssen, a Johnson & Johnson company for the development of novel iPSC-derived cell-based cancer immunotherapies.
• In April 2020, Citius Pharmaceuticals entered into an exclusive 6 month option agreement with Novellus to license novel stem-cell therapy for the acute respiratory distress syndrome (ARDS) associated with COVID-19.
• In March 2020, ElevateBio, a Cambridge-based cell and gene therapy startup received US$ 170 million Series B funding.

Frequently Asked Questions About This Report